Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05426681 · ClinicalTrials.gov registry record · Phase 1
Spinal Cord Injury Neuroprotection With Glyburide
A Phase 1 study of Acute Spinal Cord Injury, sponsored by Francis Farhadi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05426681: Recruiting Phase 1 study of Acute Spinal Cord Injury, sponsored by Francis Farhadi.
NCT05426681 is a Phase 1 study of Acute Spinal Cord Injury that is actively recruiting participants, run by Francis Farhadi. The registered enrollment target is 12 participants, below the 40-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05426681, a Phase 1 study of Acute Spinal Cord Injury, is actively recruiting participants, sponsored by Francis Farhadi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Primary Outcome
A measure of feasibility of undertaking a large phase II study among this population of patients where treatment must begin within a short injury-to-drug time window.
Conditions Studied
Interventions
- DRUG GlyBURIDE Oral Tablet
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT05426681 shows while recruiting
NCT05426681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 40-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Acute Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which GlyBURIDE Oral Tablet is the first listed.
NCT05426681 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05426681 about?
NCT05426681 is a clinical study titled "Spinal Cord Injury Neuroprotection With Glyburide". To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
What is the current status of trial NCT05426681?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-07-07. Estimated completion is 2028-05.
What conditions does trial NCT05426681 study?
This clinical trial studies the following conditions: Acute Spinal Cord Injury.
What interventions are being tested in trial NCT05426681?
The interventions under investigation include: GlyBURIDE Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05426681?
This trial is sponsored by Francis Farhadi, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05426681 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05426681's enrollment target sits among peer trials
12 8th of 8 the lowest of 8 other Acute Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
RECRUITING · NA
-
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
RECRUITING · NA
-
TSCS for Acute SCI
RECRUITING · NA
-
Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury
RECRUITING · Phase 4
-
Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study
RECRUITING · NA
-
A Pilot RCT to Improve Cognitive Processing Speed in Acute SCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI